2800 Woodlawn Drive
Suite 129
Honolulu, HI 96822
United States
808 457 1400
https://www.cardaxpharma.com
Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 10
Nome | Titolo | Retribuzione | Esercitate | Anno di nascita |
---|---|---|---|---|
Mr. David G. Watumull | Chairman & CEO | 214,96k | N/D | 1950 |
Mr. David M. Watumull | COO & CFO | 162,11k | N/D | 1982 |
Mr. Gilbert Shin | Vice President of Retail Sales & Marketing | N/D | N/D | N/D |
Cardax, Inc., a biopharmaceutical company, develops and commercializes dietary supplements for inflammatory health and pharmaceuticals for chronic diseases driven by inflammation and oxidative stress. It offers ZanthoSyn, an inflammatory supplement for health and longevity that provides astaxanthin with enhanced absorption and purity. The company sells ZanthoSyn primarily through e-commerce and wholesale channels. It is also developing CDX-101, an astaxanthin pharmaceutical candidate for cardiovascular inflammation and dyslipidemia, with a target indication of severe hypertriglyceridemia; and CDX-301, a zeaxanthin pharmaceutical candidate for macular degeneration. Cardax, Inc. is based in Honolulu, Hawaii.
L'ISS Governance QualityScore di Cardax, Inc. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.